Join Kristine Kokeny, MD and John Ward, MD as they present their multidisciplinary expertise on a range of cases pertaining to adjuvant systemic therapy for breast cancer.

The 2014 NCCN Case Manager and Medical Director Program consists of five presentations on the topics of biomarkers and targeted therapies, breast cancer, cancer survivorship, clinical trials and drug compendia, and pancreatic cancer.

Join Ingrid Mayer, MD, and Ingrid Meszoely, MD, as they present their multidisciplinary expertise on a range of cases pertaining to Breast Cancer - Advanced Disease.

Join Ingrid Mayer, MD, and Ingrid Meszoely, MD, as they present their multidisciplinary expertise on a range of cases pertaining to Breast Cancer - Advanced Disease.

This information was originally presented on March 15, 2014, at the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

The 2014 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of five webinars on the topics of biomarkers and targeted therapies, breast cancer, cancer survivorship, clinical trials and drug compendia, and pancreatic cancer.

Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family.

Quality in oncology healthcare is a moving target for stakeholders (patients, healthcare providers, and payers) in systematically identifying, planning, and executing approaches to improving quality.

Quality in oncology healthcare is a moving target for stakeholders (patients, healthcare providers, and payers) in systematically identifying, planning, and executing approaches to improving quality.

Quality in oncology healthcare is a moving target for stakeholders (patients, healthcare providers, and payers) in systematically identifying, planning, and executing approaches to improving quality.